DERIVADOS DE OXINDOL SUSTITUIDOS COMO INHIBIDORES DE PROTEINA-TIROSINA-QUINASA Y PROTEINA-SERINA/TREONINA-QUINASA

Un compuesto de **fórmula** en la que X es N, CH o CCH3; R1 es hidrógeno, nitro, carboxamida, isopropilo, hidroximetilo, piridin-4-iloetilo, etoxicarbonilo, yodo, isobutilo, 2-metil-propenilo, 2-metil-1-butenilo, 2-metil- 2-butenilo, 2-metilbutilo, ciclobutilmetilo, ciclobutilidenmetilo, 4-hidroxifenil-etilo, 4- hidroxifenil-vinilo, fenoxi, isopropoxi, pirazol-3-ilo, metilo o cloro; R2 es hidrógeno, oxazol-5-ilo, pentafluorofenoxicarbonilo, nitro, hidroxi, metoxi, metilo, triazol-1-ilo, sulfonato, carboxamida, metoxicarbonilo, bromo, yodo, aminosulfonilo, metilsulfonilo, metilaminosulfonilo, metiloxima, fenilo, N, N-dimetilaminocarbonilo, N-furan-2- ilmetilaminocarbonilo, N-(N-morfolino)etilaminocarbonilo, N-(1, 5-dimetoxibencil)aminocarbonilo, N-(imidazol-1- il)etilaminocarbonilo, N-(imidazol-1- il)propilaminocarbonilo, N-(metoxietil)aminocarbonilo, N- (hidroxietil)aminocarbonilo, N- (hidroxipropil)aminocarbonilo, N-(3-hidroxi-2, 2- dimetilpropil)aminocarbonilo, N-(pirid-3- ilmetil)aminocarbonilo, amonio cuaternario, metilcarbonilamino o isobutiloxicarbonilo. Compounds of formula (I): wherein X is N, CH, CCF3, or C(C1-12 aliphatic); R4 is sulfonic acid, C1-12 aliphatic-sulfonyl, sulfonyl-C1-12 aliphatic, C1-12 aliphatic-sulfonyl-C1-6 aliphatic, C1-6 aliphatic-amino, R7-sulfonyl, R7 sulfonyl-C1-12 aliphatic, R7-aminosulfonyl, R7-aminosulfonyl-C1-12 aliphatic, R7-sulfonylamino, R7-sulfonylamino-C1-12 aliphatic, aminosulfonylamino, di-C1-12 aliphatic amino, di-C1-12 aliphatic aminocarbonyl, di-C1-12 aliphatic aminosulfonyl, di-C1-12 aliphatic amino, di-C1-12 aliphatic aminocarbonyl, di-C1-12 aliphatic aminosulfonyl-C1-12 aliphatic, (R8)1-3-Arylamino, (R8)1-3-Arylsulfonyl, (R8)1-3-Aryl-aminosulfonyl, (R8)1-3-Aryl-sulfonylamino, Het-amino, Het-sulfonyl, Het-aminosulfonyl, aminoiminoamino, or aminoiminoaminosulfonyl, R5 is hydrogen; and further wherein R4 and R5 are optionally joined to form a fused ring, pharmaceutical formulations comprising them and their use in therapy, especially in the treatment of diseases mediated by CDK2 activity, such as alopecia induced by cancer chemotherapy or radiotherapy.